Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion 1 – Immunotherapy of cancer

2682 - Personal Antigen Selection Calculator (PASCal) for the design of personal cancer vaccines

Date

28 Sep 2019

Session

Poster Discussion 1 – Immunotherapy of cancer

Presenters

Eszter Somogyi

Citation

Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253

Authors

E. Somogyi1, Z. Csiszovszki2, O. Lorincz1, J. Toth3, L. Molnar3, W. Schönharting4, S. Urban4, T. Röhnisch5, K. Pántya2, P. Pales2, M. Megyesi2, E.R. Tőke2

Author affiliations

  • 1 Product Development, Treos Bio Zrt., Hu-8200 - Veszprém/HU
  • 2 Product Development, Treos Bio Zrt., 8200 - Veszprém/HU
  • 3 Bioinformatics, Treos Bio Zrt., 8200 - Veszprém/HU
  • 4 Oncology, PMCR GmbH, D-76135 - Karlsruhe/DE
  • 5 Hematology And Oncology, Interdisciplinary Oncology Center, D-80336 - Munich/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2682

Background

The current challenge in developing effective cancer vaccines is the accurate prediction of epitopes that induce CD8+ cytotoxic T-cell responses. Recent technological advances have enabled development of patient-specific therapeutic vaccines. However, in these vaccines only about 10-20% of the predicted neoepitopes induced CD8+ T-cell responses in patients. To overcome this limitation, we developed PASCal for improved selection of peptides (epitopes) that induce T-cell responses.

Methods

PASCal operates by 3 moduls: (1) a validated epitope database containing 108 true HLA-epitope pairs derived from 1300 tumor antigens and HLA class I and II molecules covering the HLA genotype of 26000 subjects. (2) Expression frequency-based shared tumor antigen database established for 19 indications based on > 96000 tumor biopsies. (3) Algorithm for the dentification of immunogenic peptides by the selection of personal epitopes (PEPIs) binding to ≥ 3 autologous HLA alleles. Using PASCal, personal 20mer peptide vaccines were designed for 3 HLA-genotyped cancer patients (with ovarian-, breast- and colorectal cancer). Immunogenicity of the vaccines was tested by ELISPOT and Intracellular Citokine Staining (ICS).

Results

Personalized cancer vaccines contained PEPIs from 12 disease specific tumor-antigens most frequently expressed in the patients disease. T-cell responses were induced by 100% of peptides. An average of 11/12 PEPIs induced CD8+ T-cell responses and 12/12 induced CD4+ T-cell responses in each patient. Pre-existing antigen specific T-cell reactivities were detectable against 25% of vaccine antigens (demonstrating the expression of the target vaccine antigens by the patient’s tumor), the others were induced de novo. Both CD8+ and CD4+ T-cells were polyfunctional, as evident by secretion of multiple cytokines determined by ex vivo ICS.

Conclusions

We used the largest validated database of tumor epitopes reported to-date along with an algorithm successfully selecting immunogenic peptides to develop personalized cancer vaccines. PEPIs outperform reported immunogenicity of personalized neoantigen vaccines and induced unprecedented immune responses in cancer patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

E. Somogyi: Shareholder / Stockholder / Stock options: Treos Bio Ltd. Z. Csiszovszki: Shareholder / Stockholder / Stock options: Treos Bio Ltd. O. Lorincz: Shareholder / Stockholder / Stock options: Treos Bio Ltd. J. Toth: Shareholder / Stockholder / Stock options: Treos Bio Ltd. L. Molnar: Shareholder / Stockholder / Stock options: Treos Bio Ltd. W. Schönharting: Shareholder / Stockholder / Stock options: PMCR GmbH. S. Urban: Shareholder / Stockholder / Stock options: PMCR GmbH. K. Pántya: Shareholder / Stockholder / Stock options: Treos Bio Ltd. M. Megyesi: Shareholder / Stockholder / Stock options: Treos Bio Ltd. E.R. Tőke: Shareholder / Stockholder / Stock options: Treos Bio Ltd.; Leadership role: Treos Bio Zrt. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.